Table 1.
Log10 HPV16 E7 copies per 1 nanogram of cellular DNA |
Log10 HPV18 E7 copies per 1 nanogram of cellular DNA |
|||||
---|---|---|---|---|---|---|
Variables | No. | Mean (SD) | P-value | No. | Mean (SD) | P-value |
Age at study entry (years) | ||||||
18–24 | 467 | 2.86 (1.33) | 0.09 | 188 | 3.87 (1.58) | 0.75 |
≥25 | 274 | 2.69 (1.36) | 101 | 3.80 (1.76) | ||
Race a | ||||||
White | 535 | 2.87 (1.31) | 0.03 | 175 | 3.86 (1.66) | 0.87 |
Nonwhite | 201 | 2.62 (1.41) | 113 | 3.82 (1.63) | ||
Current use of hormonal contraceptives b | ||||||
No | 372 | 2.76 (1.42) | 0.42 | 153 | 3.90 (1.79) | 0.56 |
Yes | 363 | 2.84 (1.26) | 134 | 3.78 (1.47) | ||
No. of life time male sex partners c | ||||||
0–5 | 363 | 2.80 (1.38) | 0.93 | 143 | 3.81 (1.60) | 0.68 |
≥6 | 367 | 2.79 (1.32) | 141 | 3.89 (1.69) | ||
Current smoking | ||||||
No | 408 | 2.68 (1.33) | 0.01 | 174 | 3.67 (1.61) | 0.03 |
Yes | 333 | 2.94 (1.34) | 115 | 4.11 (1.67) | ||
Coinfection with other HPV types | ||||||
No | 218 | 2.93 (1.31) | 0.09 | 72 | 4.34 (1.63) | <0.001 |
Yes | 523 | 2.74 (1.35) | 217 | 3.68 (1.62) | ||
HPV variant d | ||||||
European | 572 | 2.97 (1.21) | 0.41 | 107 | 4.26 (1.38) | 0.26 |
Non-European | 130 | 2.88 (1.18) | 144 | 4.05 (1.52) | ||
Cytology at enrollment e | ||||||
Within normal limits | 140 | 1.76 (1.31) | <0.001 | 58 | 2.79 (1.72) | <0.001 |
ASC-US | 208 | 2.76 (1.24) | 81 | 3.88 (1.48) | ||
LSIL | 248 | 3.10 (1.26) | 118 | 4.19 (1.54) | ||
HSIL | 140 | 3.39 (1.03) | 32 | 4.38 (1.47) |
NOTE. Excluded were 5 HPV16-positive women and one HPV18-positive woman who did not provide race information. A category of nonwhite includes African American, American Indian/Alaskan, or Asian/Pacific Islander women.
Excluded were 6 HPV16-positive women and 2 HPV18-positive women who did not provide information on use of hormonal contraceptives.
Excluded was 11 HPV16-positive woman and 5 HPV18-positive women who did not provide information of number of lifetime sex partners.
Excluded were 39 HPV16-positive women and 38 HPV18-positive whose enrollment samples were insufficient for variant characterization.
Excluded were 5 HPV16-positive women whose enrollment samples were inadequate for cytologic diagnosis.